{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:56:56Z","timestamp":1791316616166,"version":"4.3.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"DOI":"10.7759\/cureus.55498","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T16:51:31Z","timestamp":1709571091000},"source":"Crossref","is-referenced-by-count":8,"title":["Cryptococcosis and Cryptococcal Meningitis: A Narrative Review and the Up-to-Date Management Approach"],"prefix":"10.7759","author":[{"given":"Zaheer A","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Ghazanfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faryal","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ghazanfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushbu Z","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Kandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ked","family":"Fortuzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arundhati","family":"Dileep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitij","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham R","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, et al.. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017, 17:873-81. 10.1016\/S1473-3099(17)30243-8","journal-title":"Lancet Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42949","article-title":"Cryptococci at the brain gate: break and enter or use a Trojan horse?","volume":"120","author":"Casadevall A","year":"2010","unstructured":"Casadevall A. Cryptococci at the brain gate: break and enter or use a Trojan horse?. J Clin Invest. 2010, 120:1389-92. 10.1172\/JCI42949","journal-title":"J Clin Invest"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1086\/368091","article-title":"The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000","volume":"36","author":"Mirza SA","year":"2003","unstructured":"Mirza SA, Phelan M, Rimland D, et al.. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis. 2003, 36:789-94. 10.1086\/368091","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1086\/313843","article-title":"Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy","volume":"30","author":"Kaplan JE","year":"2000","unstructured":"Kaplan JE, Hanson D, Dworkin MS, et al.. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000, 30:S5-14. 10.1086\/313843","journal-title":"Clin Infect Dis"},{"key":"ref5","article-title":"The changing face of mycoses in patients with HIV\/AIDS","volume":"11","author":"Haddad NE","year":"2001","unstructured":"Haddad NE, Powderly WG. The changing face of mycoses in patients with HIV\/AIDS. AIDS Read. 2001, 11:365-8, 375-8.","journal-title":"AIDS Read"},{"key":"ref6","article-title":"Prevalence and correlates of cryptococcal antigen positivity among AIDS patients--United States, 1986-2012","volume":"63","author":"McKenney J","year":"2014","unstructured":"McKenney J, Smith RM, Chiller TM, Detels R, French A, Margolick J, Klausner JD. Prevalence and correlates of cryptococcal antigen positivity among AIDS patients--United States, 1986-2012. MMWR Morb Mortal Wkly Rep. 2014, 63:585-7.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043582","article-title":"Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative\/non-transplant","volume":"7","author":"Bratton EW","year":"2012","unstructured":"Bratton EW, El Husseini N, Chastain CA, et al.. Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative\/non-transplant. PLoS One. 2012, 7:e43582. 10.1371\/journal.pone.0043582","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90126-i","article-title":"Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome","volume":"91","author":"Denning DW","year":"1991","unstructured":"Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med. 1991, 91:267-72. 10.1016\/0002-9343(91)90126-i","journal-title":"Am J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park BJ","year":"2009","unstructured":"Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS. AIDS. 2009, 23:525-30. 10.1097\/QAD.0b013e328322ffac","journal-title":"AIDS"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01065-08","article-title":"Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans","volume":"77","author":"Charlier C","year":"2009","unstructured":"Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun. 2009, 77:120-7. 10.1128\/IAI.01065-08","journal-title":"Infect Immun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2020.e00700","article-title":"The detection of Cryptococcus in skeletal infection after tooth extraction in an acute myeloid leukemia patient","volume":"19","author":"Inoue H","year":"2020","unstructured":"Inoue H, Motohashi T, Ioku Y, Watanabe M, Nakajima M, Sugitatsu M. The detection of Cryptococcus in skeletal infection after tooth extraction in an acute myeloid leukemia patient. IDCases. 2020, 19:e00700. 10.1016\/j.idcr.2020.e00700","journal-title":"IDCases"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.fgb.2014.10.003","article-title":"Cryptococcosis diagnosis and treatment: what do we know now","volume":"78","author":"Perfect JR","year":"2015","unstructured":"Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: what do we know now. Fungal Genet Biol. 2015, 78:49-54. 10.1016\/j.fgb.2014.10.003","journal-title":"Fungal Genet Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.10.93","article-title":"Mechanisms of cryptococcal virulence and persistence","volume":"5","author":"Olszewski MA","year":"2010","unstructured":"Olszewski MA, Zhang Y, Huffnagle GB. Mechanisms of cryptococcal virulence and persistence. Future Microbiol. 2010, 5:1269-88. 10.2217\/fmb.10.93","journal-title":"Future Microbiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(00)00341-1","article-title":"Lipid-based amphotericin B: a review of the last 10 years of use","volume":"17","author":"Hann IM","year":"2001","unstructured":"Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents. 2001, 17:161-9. 10.1016\/s0924-8579(00)00341-1","journal-title":"Int J Antimicrob Agents"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jctc.7b00337","article-title":"Multi-phase solvation model for biological membranes: molecular action mechanism of amphotericin B","volume":"13","author":"Falc\u00f3n-Gonz\u00e1lez JM","year":"2017","unstructured":"Falc\u00f3n-Gonz\u00e1lez JM, Jim\u00e9nez-Dom\u00ednguez G, Ortega-Blake I, Carrillo-Tripp M. Multi-phase solvation model for biological membranes: molecular action mechanism of amphotericin B. J Chem Theory Comput. 2017, 13:3388-97. 10.1021\/acs.jctc.7b00337","journal-title":"J Chem Theory Comput"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes A","year":"2000","unstructured":"Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000, 46:171-9. 10.1093\/jac\/46.2.171","journal-title":"J Antimicrob Chemother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1063858","article-title":"Update on azole antifungals","volume":"29","author":"Zonios DI","year":"2008","unstructured":"Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med. 2008, 29:198-210. 10.1055\/s-2008-1063858","journal-title":"Semin Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019760","article-title":"Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis","volume":"4","author":"Kwon-Chung KJ","year":"2014","unstructured":"Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A, Bahn YS. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med. 2014, 4:a019760. 10.1101\/cshperspect.a019760","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day JN","year":"2013","unstructured":"Day JN, Chau TT, Wolbers M, et al.. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013, 368:1291-302. 10.1056\/NEJMoa1110404","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect JR","year":"2010","unstructured":"Perfect JR, Dismukes WE, Dromer F, et al.. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010, 50:291-322. 10.1086\/649858","journal-title":"Clin Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal combinations for treatment of cryptococcal meningitis in Africa","volume":"378","author":"Molloy SF","year":"2018","unstructured":"Molloy SF, Kanyama C, Heyderman RS, et al.. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018, 378:1004-17. 10.1056\/NEJMoa1710922","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199102283240902","article-title":"A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome","volume":"324","author":"Bozzette SA","year":"1991","unstructured":"Bozzette SA, Larsen RA, Chiu J, et al.. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med. 1991, 324:580-4. 10.1056\/NEJM199102283240902","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1086\/515110","article-title":"A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis","volume":"28","author":"Saag MS","year":"1999","unstructured":"Saag MS, Cloud GA, Graybill JR, et al.. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999, 28:291-6. 10.1086\/515110","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12370","article-title":"Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases","volume":"17","author":"Forrest GN","year":"2015","unstructured":"Forrest GN, Bhalla P, DeBess EE, Winthrop KL, Lockhart SR, Mohammadi J, Cieslak PR. Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases. Transpl Infect Dis. 2015, 17:467-76. 10.1111\/tid.12370","journal-title":"Transpl Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000384","article-title":"Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study","volume":"7","author":"Boulware DR","year":"2010","unstructured":"Boulware DR, Meya DB, Bergemann TL, et al.. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010, 7:e1000384. 10.1371\/journal.pmed.1000384","journal-title":"PLoS Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70945-4","article-title":"Management of Cryptococcus gattii meningoencephalitis","volume":"15","author":"Franco-Paredes C","year":"2015","unstructured":"Franco-Paredes C, Womack T, Bohlmeyer T, et al.. Management of Cryptococcus gattii meningoencephalitis. Lancet Infect Dis. 2015, 15:348-55. 10.1016\/S1473-3099(14)70945-4","journal-title":"Lancet Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Saravolatz LD","year":"2003","unstructured":"Saravolatz LD, Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003, 36:630-7. 10.1086\/367933","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2014-2020.2004","article-title":"Effects of voriconazole on Cryptococcus neoformans","volume":"48","author":"van Duin D","year":"2004","unstructured":"van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother. 2004, 48:2014-20. 10.1128\/AAC.48.6.2014-2020.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/BF01104068","article-title":"Ultrastructural study of Cryptococcus neoformans by quick-freezing and deep-etching method","volume":"121","author":"Sakaguchi N","year":"1993","unstructured":"Sakaguchi N, Baba T, Fukuzawa M, Ohno S. Ultrastructural study of Cryptococcus neoformans by quick-freezing and deep-etching method. Mycopathologia. 1993, 121:133-41. 10.1007\/BF01104068","journal-title":"Mycopathologia"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11101","article-title":"Effective voriconazole in an immunocompetent patient with amphotericin B resistant systemic cryptococcal granulomatosis","volume":"12","author":"Serraj K Sr","year":"2020","unstructured":"Serraj K Sr, Alaoui H, El Oumri AA, Barrimi M, Bachir H. Effective voriconazole in an immunocompetent patient with amphotericin B resistant systemic cryptococcal granulomatosis. Cureus. 2020, 12:e11101. 10.7759\/cureus.11101","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00212-12","article-title":"The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections","volume":"56","author":"Zhai B","year":"2012","unstructured":"Zhai B, Wu C, Wang L, Sachs MS, Lin X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother. 2012, 56:3758-66. 10.1128\/AAC.00212-12","journal-title":"Antimicrob Agents Chemother"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30127-6","article-title":"Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial","volume":"19","author":"Rhein J","year":"2019","unstructured":"Rhein J, Huppler Hullsiek K, Tugume L, et al.. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis. 2019, 19:843-51. 10.1016\/S1473-3099(19)30127-6","journal-title":"Lancet Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study","volume":"16","author":"Rhein J","year":"2016","unstructured":"Rhein J, Morawski BM, Hullsiek KH, et al.. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016, 16:809-18. 10.1016\/S1473-3099(16)00074-8","journal-title":"Lancet Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00765-13","article-title":"Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo","volume":"5","author":"Butts A","year":"2014","unstructured":"Butts A, Koselny K, Chabrier-Rosell\u00f3 Y, et al.. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio. 2014, 5:e00765-13. 10.1128\/mBio.00765-13","journal-title":"mBio"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.68929","article-title":"An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis","volume":"10","author":"Ngan NT","year":"2021","unstructured":"Ngan NT, Thanh Hoang Le N, Vi Vi NN, et al.. An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. eLife. 2021, 10:e68929. 10.7554\/eLife.68929","journal-title":"eLife"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-\u03b3 immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial","volume":"26","author":"Jarvis JN","year":"2012","unstructured":"Jarvis JN, Meintjes G, Rebe K, et al.. Adjunctive interferon-\u03b3 immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012, 26:1105-13. 10.1097\/QAD.0b013e3283536a93","journal-title":"AIDS"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.9.5753","article-title":"Protection from direct cerebral cryptococcus infection by interferon-gamma-dependent activation of microglial cells","volume":"178","author":"Zhou Q","year":"2007","unstructured":"Zhou Q, Gault RA, Kozel TR, Murphy WJ. Protection from direct cerebral cryptococcus infection by interferon-gamma-dependent activation of microglial cells. J Immunol. 2007, 178:5753-61. 10.4049\/jimmunol.178.9.5753","journal-title":"J Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/BF01575121","article-title":"Trends in immunotherapy of fungal infections","volume":"16","author":"Kullberg BJ","year":"1997","unstructured":"Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis. 1997, 16:51-5. 10.1007\/BF01575121","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1080\/13550280500384982","article-title":"Differential responses of human brain cells to West Nile virus infection","volume":"11","author":"Cheeran MC","year":"2005","unstructured":"Cheeran MC, Hu S, Sheng WS, Rashid A, Peterson PK, Lokensgard JR. Differential responses of human brain cells to West Nile virus infection. J Neurovirol. 2005, 11:512-24. 10.1080\/13550280500384982","journal-title":"J Neurovirol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.7.4189","article-title":"Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus","volume":"175","author":"Aravalli RN","year":"2005","unstructured":"Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard JR. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol. 2005, 175:4189-93. 10.4049\/jimmunol.175.7.4189","journal-title":"J Immunol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2004.10.020","article-title":"Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii","volume":"35","author":"Suzuki Y","year":"2005","unstructured":"Suzuki Y, Claflin J, Wang X, Lengi A, Kikuchi T. Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii. Int J Parasitol. 2005, 35:83-90. 10.1016\/j.ijpara.2004.10.020","journal-title":"Int J Parasitol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2008.29.3143","article-title":"Interleukin-2 treatment for persistent cryptococcal meningitis in a child with idiopathic CD4(+) T lymphocytopenia","volume":"29","author":"Yilmaz-Demirdag Y","year":"2008","unstructured":"Yilmaz-Demirdag Y, Wilson B, Lowery-Nordberg M, Bocchini JA Jr, Bahna SL. Interleukin-2 treatment for persistent cryptococcal meningitis in a child with idiopathic CD4(+) T lymphocytopenia. Allergy Asthma Proc. 2008, 29:421-4. 10.2500\/aap.2008.29.3143","journal-title":"Allergy Asthma Proc"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005836","article-title":"Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans","volume":"11","author":"Chatterjee S","year":"2017","unstructured":"Chatterjee S, Tatu U. Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans. PLoS Negl Trop Dis. 2017, 11:e0005836. 10.1371\/journal.pntd.0005836","journal-title":"PLoS Negl Trop Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix870","article-title":"Long-term mortality and disability in cryptococcal meningitis: a systematic literature review","volume":"66","author":"Pasquier E","year":"2018","unstructured":"Pasquier E, Kunda J, De Beaudrap P, et al.. Long-term mortality and disability in cryptococcal meningitis: a systematic literature review. Clin Infect Dis. 2018, 66:1122-32. 10.1093\/cid\/cix870","journal-title":"Clin Infect Dis"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056269","article-title":"Epidemiology of cryptococcal meningitis in the US: 1997-2009","volume":"8","author":"Pyrgos V","year":"2013","unstructured":"Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS One. 2013, 8:e56269. 10.1371\/journal.pone.0056269","journal-title":"PLoS One"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2011.607854","article-title":"Cryptococcus gattii: where do we go from here?","volume":"50","author":"Harris J","year":"2012","unstructured":"Harris J, Lockhart S, Chiller T. Cryptococcus gattii: where do we go from here?. Med Mycol. 2012, 50:113-29. 10.3109\/13693786.2011.607854","journal-title":"Med Mycol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.01.054","article-title":"Fungal infections in transplant recipients receiving alemtuzumab","volume":"37","author":"Nath DS","year":"2005","unstructured":"Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc. 2005, 37:934-6. 10.1016\/j.transproceed.2005.01.054","journal-title":"Transplant Proc"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.6.2395","article-title":"Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy","volume":"124","author":"Hage CA","year":"2003","unstructured":"Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest. 2003, 124:2395-7. 10.1378\/chest.124.6.2395","journal-title":"Chest"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3400280","article-title":"Cryptococcosis","volume":"41","author":"Zavala S","year":"2020","unstructured":"Zavala S, Baddley JW. Cryptococcosis. Semin Respir Crit Care Med. 2020, 41:69-79. 10.1055\/s-0039-3400280","journal-title":"Semin Respir Crit Care Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1378\/chest.98.5.1060","article-title":"Pulmonary manifestations of disseminated cryptococcosis in patients with AIDS","volume":"98","author":"Chechani V","year":"1990","unstructured":"Chechani V, Kamholz SL. Pulmonary manifestations of disseminated cryptococcosis in patients with AIDS. Chest. 1990, 98:1060-6. 10.1378\/chest.98.5.1060","journal-title":"Chest"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/18.3.369","article-title":"Clinical epidemiological study of 171 cases of cryptococcosis","volume":"18","author":"Rozenbaum R","year":"1994","unstructured":"Rozenbaum R, Gon\u00e7alves AJ. Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis. 1994, 18:369-80. 10.1093\/clinids\/18.3.369","journal-title":"Clin Infect Dis"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/13.1.64","article-title":"Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome","volume":"13","author":"Cameron ML","year":"1991","unstructured":"Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis. 1991, 13:64-7. 10.1093\/clinids\/13.1.64","journal-title":"Rev Infect Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.3.628","article-title":"Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS","volume":"21","author":"Meyohas MC","year":"1995","unstructured":"Meyohas MC, Roux P, Bollens D, et al.. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis. 1995, 21:628-33. 10.1093\/clinids\/21.3.628","journal-title":"Clin Infect Dis"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-015-9880-7","article-title":"Systemic review of published reports on primary cutaneous cryptococcosis in immunocompetent patients","volume":"180","author":"Du L","year":"2015","unstructured":"Du L, Yang Y, Gu J, Chen J, Liao W, Zhu Y. Systemic review of published reports on primary cutaneous cryptococcosis in immunocompetent patients. Mycopathologia. 2015, 180:19-25. 10.1007\/s11046-015-9880-7","journal-title":"Mycopathologia"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20176343","article-title":"Disseminated cryptococcosis with skin lesions: report of a case series","volume":"92","author":"Hayashida MZ","year":"2017","unstructured":"Hayashida MZ, Seque CA, Pasin VP, Enokihara MM, Porro AM. Disseminated cryptococcosis with skin lesions: report of a case series. An Bras Dermatol. 2017, 92:69-72. 10.1590\/abd1806-4841.20176343","journal-title":"An Bras Dermatol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis","volume":"370","author":"Boulware DR","year":"2014","unstructured":"Boulware DR, Meya DB, Muzoora C, et al.. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014, 370:2487-98. 10.1056\/NEJMoa1312884","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1437","article-title":"Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies","volume":"42","author":"Casadevall A","year":"1998","unstructured":"Casadevall A, Cleare W, Feldmesser M, et al.. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother. 1998, 42:1437-46. 10.1128\/AAC.42.6.1437","journal-title":"Antimicrob Agents Chemother"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.767582","article-title":"A monoclonal antibody to Cryptococcus neoformans glucuronoxylomannan manifests hydrolytic activity for both peptides and polysaccharides","volume":"292","author":"Bowen A","year":"2017","unstructured":"Bowen A, Wear MP, Cordero RJ, Oscarson S, Casadevall A. A monoclonal antibody to Cryptococcus neoformans glucuronoxylomannan manifests hydrolytic activity for both peptides and polysaccharides. J Biol Chem. 2017, 292:417-34. 10.1074\/jbc.M116.767582","journal-title":"J Biol Chem"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.952-958.2005","article-title":"Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis","volume":"49","author":"Larsen RA","year":"2005","unstructured":"Larsen RA, Pappas PG, Perfect J, et al.. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother. 2005, 49:952-8. 10.1128\/AAC.49.3.952-958.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05954-11","article-title":"T-2307 causes collapse of mitochondrial membrane potential in yeast","volume":"56","author":"Shibata T","year":"2012","unstructured":"Shibata T, Takahashi T, Yamada E, et al.. T-2307 causes collapse of mitochondrial membrane potential in yeast. Antimicrob Agents Chemother. 2012, 56:5892-7. 10.1128\/AAC.05954-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/jof7020130","article-title":"Review of T-2307, an investigational agent that causes collapse of fungal mitochondrial membrane potential","volume":"7","author":"Wiederhold NP","year":"2021","unstructured":"Wiederhold NP. Review of T-2307, an investigational agent that causes collapse of fungal mitochondrial membrane potential. J Fungi (Basel). 2021, 7:130. 10.3390\/jof7020130","journal-title":"J Fungi (Basel)"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01159-07","article-title":"In vitro and in vivo antifungal activities of T-2307, a novel arylamidine","volume":"52","author":"Mitsuyama J","year":"2008","unstructured":"Mitsuyama J, Nomura N, Hashimoto K, et al.. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008, 52:1318-24. 10.1128\/AAC.01159-07","journal-title":"Antimicrob Agents Chemother"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra WJ","year":"2014","unstructured":"Hoekstra WJ, Garvey EP, Moore WR, Rafferty SW, Yates CM, Schotzinger RJ. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg Med Chem Lett. 2014, 24:3455-8. 10.1016\/j.bmcl.2014.05.068","journal-title":"Bioorg Med Chem Lett"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00570-17","article-title":"Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14\u03b1-demethylase provides insights into its broad-spectrum antifungal activity","volume":"61","author":"Hargrove TY","year":"2017","unstructured":"Hargrove TY, Garvey EP, Hoekstra WJ, et al.. Crystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14\u03b1-demethylase provides insights into its broad-spectrum antifungal activity. Antimicrob Agents Chemother. 2017, 61:e00570-17. 10.1128\/AAC.00570-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02233-18","article-title":"The fungal Cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris","volume":"63","author":"Wiederhold NP","year":"2019","unstructured":"Wiederhold NP, Lockhart SR, Najvar LK, et al.. The fungal Cyp51-specific inhibitor VT-1598 demonstrates in vitro and in vivo activity against Candida auris. Antimicrob Agents Chemother. 2019, 63:e02233-18. 10.1128\/AAC.02233-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky242","article-title":"The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis","volume":"73","author":"Garvey EP","year":"2018","unstructured":"Garvey EP, Sharp AD, Warn PA, Yates CM, Schotzinger RJ. The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis. J Antimicrob Chemother. 2018, 73:2815-22. 10.1093\/jac\/dky242","journal-title":"J Antimicrob Chemother"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.5b00134","article-title":"Antitumor\/antifungal celecoxib derivative AR-12 is a non-nucleoside inhibitor of the ANL-family adenylating enzyme acetyl CoA synthetase","volume":"2","author":"Koselny K","year":"2016","unstructured":"Koselny K, Green J, Favazzo L, Glazier VE, DiDone L, Ransford S, Krysan DJ. Antitumor\/antifungal celecoxib derivative AR-12 is a non-nucleoside inhibitor of the ANL-family adenylating enzyme acetyl CoA synthetase. ACS Infect Dis. 2016, 2:268-80. 10.1021\/acsinfecdis.5b00134","journal-title":"ACS Infect Dis"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01061-16","article-title":"The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis","volume":"60","author":"Koselny K","year":"2016","unstructured":"Koselny K, Green J, DiDone L, et al.. The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis. Antimicrob Agents Chemother. 2016, 60:7115-27. 10.1128\/AAC.01061-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe NA","year":"2012","unstructured":"Watanabe NA, Miyazaki M, Horii T, Sagane K, Tsukahara K, Hata K. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrob Agents Chemother. 2012, 56:960-71. 10.1128\/AAC.00731-11","journal-title":"Antimicrob Agents Chemother"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00523-18","article-title":"In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus","volume":"62","author":"Shaw KJ","year":"2018","unstructured":"Shaw KJ, Schell WA, Covel J, et al.. In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018, 62:e00523-18. 10.1128\/AAC.00523-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01623-22","article-title":"Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers","volume":"67","author":"Hodges MR","year":"2023","unstructured":"Hodges MR, Ople E, Wedel P, et al.. Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers. Antimicrob Agents Chemother. 2023, 67:e0162322. 10.1128\/aac.01623-22","journal-title":"Antimicrob Agents Chemother"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2021.03.012","article-title":"Cryptococcosis","volume":"35","author":"Gushiken AC","year":"2021","unstructured":"Gushiken AC, Saharia KK, Baddley JW. Cryptococcosis. Infect Dis Clin North Am. 2021, 35:493-514. 10.1016\/j.idc.2021.03.012","journal-title":"Infect Dis Clin North Am"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00312-18","article-title":"Miltefosine has a postantifungal effect and induces apoptosis in Cryptococcus yeasts","volume":"62","author":"Spadari CC","year":"2018","unstructured":"Spadari CC, Vila T, Rozental S, Ishida K. Miltefosine has a postantifungal effect and induces apoptosis in Cryptococcus yeasts. Antimicrob Agents Chemother. 2018, 62:e00312-18. 10.1128\/AAC.00312-18","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/234774-cryptococcosis-and-cryptococcal-meningitis-a-narrative-review-and-the-up-to-date-management-approach","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T16:51:35Z","timestamp":1709571095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/234774-cryptococcosis-and-cryptococcal-meningitis-a-narrative-review-and-the-up-to-date-management-approach"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":73,"URL":"https:\/\/doi.org\/10.7759\/cureus.55498","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}